Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Clinical trial NCT01622569 · COMPLETED
Trial details
- NCT number
- NCT01622569
- Sponsor
- Optinose US Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-19
- Primary completion
- 2015-08-06
- Enrollment
- 323
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.